The patient's medical history included obesity, asthma, possible sleep apnea, and a potentially deviated septum.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...

HealthDay News — The US Department of Health and Human Services and the National Institutes of Health announced a new initiative called “Generation Gold Standard” to develop next-generation, universal ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

“Interchangeability of Selarsdi with Stelara will further enable increased access for US patients to more affordable treatment options and contribute to lowering health care costs, which is an ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on ...

The drug, called medetomidine, is used by veterinarians to sedate pets. It’s similar to xylazine, another animal drug that has already made the US opioid crisis worse, The Associated Press reported.

Doctors say for diseases like measles or polio, they argue it may be wrong to withhold vaccines from people in a placebo group when those vaccines have already been shown to be effective.

At Sensient Technologies, one of the world’s largest dyemakers, scientists are working hard to find natural alternatives.

HealthDay News — Six in 10 women believe they will hit menopause in their 40s, according to survey results released April 8 by The Ohio State University Wexner Medical Center in Columbus.

Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; new ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...